Zydus Lifesciences gets final FDA approval for prostate cancer drug
The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 mg. Shares of Zydus Lifesciences Ltd ended at ₹901.15, up by ₹7.85, or 0.88%, on the BSE.